Join our daily newsletter At The Bell to receive exclusive market insights
- Proteomics International (PIQ) is preparing to present its latest results from the company’s novel blood test for oesophageal adenocarcinoma
- The company will showcase results from its PromarkerEso blood test at the 19th ISDE World Congress for Esophageal Diseases in Toronto, Canada
- Oesophageal adenocarcinoma is a lethal disease, with a mere five-year survival rate of just 20 per cent
- Shares last traded at 90 cents
Proteomics International (PIQ) has made significant progress in the fight against oesophageal cancer as it prepares to present at the 19th ISDE World Congress for Esophageal Diseases in Toronto, Canada.
The company will showcase findings from its novel blood test, PromarkerEso, designed to detect this deadly cancer.
Oesophageal adenocarcinoma is a lethal disease, with a mere five-year survival rate of just 20 per cent. It often originates from chronic acid reflux, underscoring the critical importance of early detection.
Current screening methods involve costly specialist endoscopy procedures, which can amount to US$2750 per patient in the United States.
The test offers new hope for early and accurate detection of oesophageal adenocarcinoma, the most common form of oesophageal cancer.
“We’ve refined our diagnostic models to correctly identify 89 per cent of patients with oesophageal adenocarcinoma and 92 per cent of patients without the disease,” PIQ Managing Director Dr Richard Lipscombe said.
“This means we could have a simple blood test to determine who would benefit from an endoscopy.”
PromarkerEso utilises protein biomarkers in the blood to diagnose both oesophageal adenocarcinoma and its precursor condition, Barrett’s oesophagus.
Approximately 10-15 per cent of patients with chronic acid reflux develop Barrett’s oesophagus, significantly increasing their risk of oesophageal cancer.
The potential impact of this test is profound, not only in saving lives but also in reducing healthcare costs.
Proteomics International is currently working on streamlining the biomarker measurements for clinical use in the United States.
PIQ is also collaborating with key opinion leaders (KOLs) to facilitate the early adoption of PromarkerEso.
Proteomics International shares last traded at 90 cents.
